Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Cantor Fitzgerald
US Department of Justice
AstraZeneca
Deloitte
Accenture
Teva
Argus Health
Federal Trade Commission

Generated: April 21, 2018

DrugPatentWatch Database Preview

RENOVUE-65 Drug Profile

« Back to Dashboard

When do Renovue-65 patents expire, and what generic alternatives are available?

Renovue-65 is a drug marketed by Bracco and is included in one NDA.

The generic ingredient in RENOVUE-65 is iodamide meglumine. There is one drug master file entry for this compound. Additional details are available on the iodamide meglumine profile page.
Summary for RENOVUE-65
US Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: 4
Patent Applications: 22
Drug Prices:see details
DailyMed Link:RENOVUE-65 at DailyMed
Drug patent expirations by year for RENOVUE-65
Medical Subject Heading (MeSH) Categories for RENOVUE-65
Synonyms for RENOVUE-65
1-Deoxy-1-(methylamino)-D-glucitol alpha,5-diacetamido-2,4,6-triiodo-m-toluate
16240-58-7
18656-21-8
3-acetamido-5-(acetamidomethyl)-2,4,6-triiodobenzoic acid; (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol
523-89-7
63087-14-9
6X283535A3
AC1L1GXJ
alpha,5-Diacetamido-2,4,6-triiodo-m-toluic acid compound with 1-deoxy-1-(methylamino)-D-glucitol (1:1)
Benzoic acid, 3-(acetylamino)-5-((acetylamino)methyl)-2,4,6-triiodo-, compound with 1-deoxy-1-(methylamino)-D-glucitol (1:1)
CA003333
CHEMBL1201172
Conraxin H
D01979
DTXSID90171915
EINECS 242-480-6
Glucitol, 1-deoxy-1-(methylamino)-, alpha,5-diacetamido-2,4,6-triiodo-m-toluate (salt), D-
Iodamide 300
IODAMIDE MEGLUMINE
Iodamide meglumine (USAN)
Iodamide Meglumine [USAN]
Iodamide methylglucamine
Iodamide N-methyl-D-glucamine salt
Isteropac E.R
Isteropac E.R.
Jodamid methylglucaminsalz
Jodamid methylglucaminsalz [German]
LS-71355
Meglumine iodamide
Meglumine Iodamide Injection
Meglumine sodium iodamide injection
Meglumine Sodium Iodamide Injection (JAN)
Meglumine Sodium Iodamide Injection [JAN]
N-METHYL-D(-)-GLUCAMINE; IODAMIDE
Opacist E.R
Opacist E.R.
Renovue
Renovue-65 (TN)
Renovue-DIP
SCHEMBL720586
UNII-6X283535A3

US Patents and Regulatory Information for RENOVUE-65

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bracco RENOVUE-65 iodamide meglumine INJECTABLE;INJECTION 017902-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Fish and Richardson
UBS
Federal Trade Commission
Healthtrust
Johnson and Johnson
Fuji
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.